New Customers Get 10% Off – Use Code: LUX10

CJC NO DAC/IPAMORELIN

5.0 Reviews

CJC/Ipa BlendMod GRF 1-29 + IpamorelinModified GRF + Ipamorelin

A carefully crafted peptide combination studied for its effect on growth hormone release through simultaneous activation of GHRH and ghrelin receptors in experimental research models. Premium Research Peptide.

All products currently listed on this site are for research purposes only.

Original price was: $100.00.Current price is: $90.00.

2 Day FAST Shipping

99%+ Purity Tests

Ships from USA

USA Lab Tested

We accept :

Certificate of Analysis

Third Party Tested by Freedom Diagnostics

How CJC NO DAC/IPAMORELIN Works

The Science, Simplified

Dual-Pathway Receptor Synergy

This blend combines two complementary secretagogues. CJC-1295 (No DAC) is a GHRH analog that targets the GHRH receptor, while Ipamorelin is a selective ghrelin receptor agonist.
Key insight: When used together, research shows a “synergy factor” of approximately 2.7x. While GHRH alone might produce a 20-fold GH increase, the combination has been observed to yield up to a 54-fold increase by activating the pituitary from two different angles simultaneously.

Preservation of Pulsatile GH Patterns

The "No DAC" (Drug Affinity Complex) version of CJC-1295 has a shorter half-life (30 minutes to 2 hours) compared to DAC versions.

Key insight: This allows the body to maintain its natural, pulsatile growth hormone release pattern rather than a constant “bleed.” In research, this is considered more physiological and reduces the risk of pituitary desensitization or “GH bleed.”

Selective Ipamorelin Signaling

Ipamorelin is the first truly selective GH secretagogue. Unlike older GHRPs (like GHRP-2 or GHRP-6), it does not significantly activate the receptors responsible for cortisol or prolactin release.

Key insight: Research indicates that Ipamorelin amplifies the GH pulse with high selectivity, without the increased appetite, water retention, or stress-hormone elevation observed with less selective analogs, making it a highly precise tool for metabolic studies.

Research Handling Notes

What research literature describes

This blend is noted for its high stability in preclinical research, largely due to the selectivity of Ipamorelin and the physiological nature of the "No DAC" CJC-1295.

🧿 Laboratory Handling Notes

20%

Store lyophilized at -20°C

mild

15%

Reconstitute with bacteriostatic water

mild

12%

Protect from light

mild

Safety Advantage

High Selectivity

  • Zero Cortisol Spike: Ipamorelin does not elevate ACTH or cortisol, preserving the subject's natural stress response.
  • Prolactin Neutrality: Research data shows no significant impact on prolactin levels in research models.
  • Reversibility: Because the "No DAC" formulation clears the system quickly, any observed effects are rapidly reversible upon cessation of exposure in research models.

Compound Information

Technical specifications for each component

🔬 Molecular Profile

GHRH Analog Component

Other names

Mod GRF 1-29, Modified GRF

Type

GHRH analog

Amino Acids

29

Molecular Weight

~3,367 g/mol

Mechanism

GHRH receptor agonist

Half-life (No DAC)

30 min - 2 hours

PubChem Databases

🧊 Storage Requirements

Selective GHRP Component

This combination is designed to support synergistic growth hormone release through dual-pathway activation while helping preserve a natural pulsatile secretion pattern.

Lyophilized (powder)

Store at -20°C

Stable up to 24 months

Reconstituted solution

Store at 2–8°C

Use within 14–30 days

Handling Notes

Protect from light exposure

Avoid repeated freeze–thaw cycles

📋 Blend Information

Why This Combination

This combination is designed to support synergistic growth hormone release through dual-pathway activation while helping preserve a natural pulsatile secretion pattern.

Classification

Growth hormone releasing peptides

Origin

CJC-1295 (No DAC): synthetic GHRH analog

Research Scop

Studied for pulsatile growth hormone release stimulation

PubMed / Studies

500+ research publications across GH-axis modulation

Raun et al., 1998

Frequently Asked Questions

Common questions about CJC NO DAC/IPAMORELIN

DAC stands for Drug Affinity Complex, which extends the half-life of CJC-1295 to several days. The "No DAC" version (also called Mod GRF 1-29) has a shorter half-life, which mimics the body’s natural pulsatile release of growth hormone. This is generally preferred in research to avoid over-stimulating the pituitary gland.
They work on different receptors. CJC-1295 acts as a "gas pedal" to start GH production, while Ipamorelin acts as a "brake-releaser" (by inhibiting somatostatin) and an amplifier. Together, they create a much stronger GH pulse than either could achieve on its own.
No. Unlike GHRP-6, which strongly activates the ghrelin receptors in the stomach associated with appetite signaling, Ipamorelin is highly selective for the pituitary receptors. In research models, this selectivity is associated with minimal ghrelin-receptor activity compared to older peptides.
The lyophilized powder is reconstituted with Bacteriostatic Water. Because it contains two different peptides, it is important to swirl the vial very gently to ensure a homogenous solution without damaging the delicate peptide structures.
No. While the individual components have been through various stages of clinical trials, the blend is currently classified as an investigational research compound. it is not approved for human use and is sold strictly for laboratory evaluation.

Sources & References

Peer-reviewed research

Journal of Clinical Endocrinology & Metabolism

Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults

2006

Teichman SL, Neale A, Lawrence B et al.

View Source

European Journal of Endocrinology

Ipamorelin, the first selective growth hormone secretagogue

1998

Raun K, Hansen BS, Johansen NL et al.

View Source

Journal of Clinical Endocrinology & Metabolism

On the actions of the growth hormone-releasing hexapeptide, GHRP

1991

Bowers CY, Reynolds GA, Durham D et al.

View Source

Translational Andrology and Urology

A Review of Growth Hormone Secretagogues

2018

Sigalos JT, Pastuszak AW

View Source

Translational Andrology and Urology

A Review of Growth Hormone Secretagogues

2018

Sigalos JT, Pastuszak AW

View Source
  • Important Research Notice

Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.

All research data and findings presented on this page are sourced from peer-reviewed journals and official publications. They are provided for educational reference only and should not be interpreted as medical advice or product claims.

By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations.

My Account
Follow Us
Linkedin X-twitter Icon-instagram-1 Facebook-square